2026-05-22T00:58:05Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/148732024-11-29T18:46:17Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19609col_20.500.12105_16988

00925njm 22002777a 4500 dc Rodríguez-Mora, Sara author Corona, Magdalena author Torres, Montserrat author Casado-Fernández, Guiomar author García-Pérez, Javier author Ramos-Martín, Fernando author Vigon-Hernandez, Lorena author Manzanares, Mario author Mateos, Elena author Martín-Moro, Fernando author Zurdo-Castronuño, Alejandro author Murciano-Antón, María Aranzazu author Alcamí, José author Perez-Olmeda, Mayte author López-Jiménez, Javier author García-Gutiérrez, Valentín author Coiras, Mayte author Multidisciplinary Group of Study of COVID-19 (MGS-COVID) author 2022-05-16 Individuals with oncohematological diseases (OHD) may develop an impaired immune response against vaccines due to the characteristics of the disease or to its treatment. Humoral response against SARS-CoV-2 has been described to be suboptimal in these patients, but the quality and efficiency of the cellular immune response has not been yet completely characterized. In this study, we analyzed the early humoral and cellular immune responses in individuals with different OHD after receiving one dose of an authorized vaccine against SARS-CoV-2. Humoral response, determined by antibodies titers and neutralizing capacity, was overall impaired in individuals with OHD, except for the cohort of chronic myeloid leukemia (CML), which showed higher levels of specific IgGs than healthy donors. Conversely, the specific direct cytotoxic cellular immunity response (DCC) against SARS-CoV-2, appeared to be enhanced, especially in individuals with CML and chronic lymphocytic leukemia (CLL). This increased cellular immune response, developed earlier than in healthy donors, showed a modest cytotoxic activity that was compensated by significantly increased numbers, likely due to the disease or its treatment. The analysis of the immune response through subsequent vaccine doses will help establish the real efficacy of COVID-19 vaccines in individuals with OHD. J Clin Med. 2022 May 16;11(10):2803. 10.3390/jcm11102803 2077-0383 2077-0383 Journal of Cnical Medicine 35628927 http://hdl.handle.net/20.500.12105/14873 COVID-19 vaccine Cytotoxic response Early immune Hematological malignancies Humoral response Early Cellular and Humoral Responses Developed in Oncohematological Patients after Vaccination with One Dose against COVID-19